

Anti-SLAMF7 (Elotuzumab), Humanized Antibody

09/20

CATALOG NO.: A2218-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG1 monoclonal antibody that specifically targets Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7), a cell surface glycoprotein that is highly expressed on NK and multiple myeloma (MM) cells. The antibody has a dual mechanism of action: the direct effect involves the binding of the antibody to the Fc receptor (CD16), an extracellular portion of SLAMF7 on NK cells which ultimately triggers cell death via antibody-dependent cell cytotoxicity (ADCC); the indirect effect involves cell tagging wherein the Fab portion of the antibody binds to SLAMF7 on MM cells. These cells are recognized by NK cells that cause release of degranulated cytotoxic granules and lysis of MM cells. The original antibody was approved by the FDA as a combination treatment for patients with relapsed multiple myeloma.

ALTERNATE NAMES: BMS-901608, HuLuc63, PDL063, PDL-06319A, CS1, CD319, CRACC

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human SLAMF7

CAS NUMBER: 915296-00-3

MOLECULAR WEIGHT: 148.1 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-CTLA-4 (Ipilimumab), Humanized Antibody (A2110)
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)
 Anti-CD38 (Daratumumab), Human IgG1 Antibody (A2151)

FOR RESEARCH USE ONLY! Not to be used on humans.